Saturday, December 12, 2020

All times are Eastern Standard Time

Welcome

7:45 a.m. – 8:00 a.m.
Cathleen C. Gates
Interim, Chief Executive Officer
American College of Cardiology

Athena Poppas, MD, FACC
President
American College of Cardiology

Norma Keller, MD, FACC
President, New York State Chapter
American College of Cardiology

Cardiovascular & Coronary Artery Disease — Challenges in 2020
Session I: Evolving New Frontiers Ready for Practice
Chair: Athena Poppas, MD, FACC

8:00 a.m. – 8:25 a.m.
Clinical, Genetic & Noninvasive Imaging (3D-US, PET, MRI) Stratification
Predicting Progression of CVD and Cognitive Dysfunction
Valentin Fuster, MD, PhD, MACC
New York, NY

8:25 a.m. – 8:50 a.m.
CTA Imaging in the Full Assessment of Coronary Disease
Noninvasive Approach to Plaque Anatomy, Ischemia & Risk
Patrick W. Serruys, MD, FACC
Rotterdam, Netherlands
8:50 a.m. – 9:15 a.m.
Stratification of Angina due to Coronary Microvascular Dysfunction
Epicardial Spastic Phenomenon & INOCA in Context
Divaka Perera, MD
London, England, United Kingdom

9:15 a.m. – 9:35 a.m.
Coronary 18F-Sodium Fluoride Uptake Imaging
Predicts Activity and Outcomes in Patients with Coronary Disease
Marc Dweck, MB ChB, PhD, FACC
Edinburgh, Scotland, United Kingdom

9:35 a.m. – 10:00 a.m.
Panel Discussion
Panelists: Drs. Dweck, Fuster, Perera and Serruys

10:00 a.m. – 10:25 a.m.
Break

Session II: Acute Coronary Syndrome Complexities
Chair: Deepak L. Bhatt, MD, MPH, FACC

10:25 a.m. – 10:45 a.m.
STEMI - PCI Complete Revascularization vs Culprit Lesion only
Multivessel Disease Without or With Cardiogenic Shock
Shamir Mehta, MD, FACC
Hamilton, ON, Canada

10:45 a.m. – 11:05 a.m.
COVID 19 - Acute Coronary / Myocardial Syndromes & Follow Up
Certainties & Uncertainties on Incidence, Pathogenesis & Management
Deepak L. Bhatt, MD, MPH, FACC
Boston, MA

11:05 a.m. – 11:35 a.m.
Antithrombotics in High vs Low Risk Patients & with vs Without PCI
Evolving Path Towards Monotherapy - For How Long, P2Y12 Inhib.? vs NOACS
Roxana Mehran, MD, FACC
New York, NY

11:35 a.m. – 12:00 Noon
Panel Discussion
Panelists: Drs. Bhatt, Mehran and Mehta

12:00 Noon – 1:00 p.m.
Lunch Break
Session III: Chronic Coronary Disease, Systemic Arterial Disease, Stroke and Pulmonary Embolism
Chair: Dipti Itchhaporia, MD, FACC

1:00 p.m. – 1:25 p.m.
Stable Coronary Multivessel Disease
Five Variables - Clinical, Anatomy, LV, Ischemia, Microcirculation
Three Approaches of Managements - PCI vs CABG vs OMT
Valentin Fuster, MD, PhD, MACC
New York, NY

1:25 p.m. – 1:50 p.m.
Coronary & Systemic Arterial Disease –
The Role of New Oral Anticoagulants (NOACS)
John Eikelboom, MBBS
Hamilton, ON, Canada

1:50 p.m. – 2:15 p.m.
Ischemic Strokes & Cerebral Hemorrhage
Acute Management vs Primary & Secondary Prevention
Priyank Khandelwal, MD
Newark, NJ

2:15 p.m. – 2:40 p.m.
Pulmonary Emboli - Diagnosis Based on Suspicion
Management Based on the Acute Severity and Degree of Chronic PH
Samuel Z. Goldhaber, MD, FACC
Boston, MA

2:40 p.m. – 3:05 p.m.
Panel Discussion
Panelists: Drs. Eikelboom, Fuster, Goldhaber and Khandelwal

3:05 p.m. – 3:30 p.m.
Break

Session IV: Trends and Challenges of Approaching Prevention – Health Factors
Chair: Pamela B. Morris, MD, FACC

3:30 p.m. – 3:55 p.m.
Obesity – From Genetics & Behavior to Pharmacotherapy & Bariatric Surgery
Carl J. Lavie, MD, FACC
New Orleans, LA

3:55 p.m. – 4:20 p.m.
Lipid-Modifying Agents - From Statins to PCSK9 Inhibitors
Nell J. Stone, MD, FACC
Chicago, IL
4:20 p.m. – 4:45 p.m.
Diabetic Agents – From Metformin To SGLT2 Inhib. & GLP1 Receptor Agonists
David Preiss, MD, PhD
Oxford, England, United Kingdom

4:45 p.m. – 5:10 p.m.
Changing Patterns of Mortality And Their Causes --- The PURE Study in 21 Countries
Salim Yusuf, DPhil, FACC
Hamilton, ON, Canada

5:10 p.m. – 5:35 p.m.
The Present Global Burden of Cardiovascular Diseases and Risk Factors
George A. Mensah, MD, FACC
Bethesda, MD

5:35 p.m. – 6:00 p.m.
Panel Discussion
Panelists: Drs. Lavie, Mensah, Preiss, Stone and Yusuf

6:00 p.m. Adjourn

Sunday, December 13, 2020

All times are Eastern Standard Time

Cardio-Pulmonary and Electrical Failure 2020
Session V: Myocardial Disease and Heart Failure; Basis for Management
Chair: Clyde W. Yancy, MD, MACC

8:00 a.m. – 8:20 a.m.
Evolving Imaging (MRI, PET) for 7 Myocardial Diseases
Myocarditis, Dilated CM, Hypertrophic CM, Noncompaction LV,
Amyloid CM, Sarcoid & Takotsubo
Diagnostic & Prognostic Tools
Jeroen J. Bax, MD, PhD, FACC
Leiden, Netherlands

8:20 a.m. – 8:40 a.m.
Evolving Clinical Genetics & Omics in 7 Myocardial Diseases
Which Subgroup or When Should be Gene Tested
William J. McKenna, MD, FACC
London, England, United Kingdom

8:40 a.m. – 9:00 a.m.
Evolving Understanding of HFrEF vs HfIEF vs HFpEF Phenotypes
Therapeutic Role of SGLT2 Inhibitors & ARNIs in the 3 Entities
Clyde W. Yancy, MD, MACC
Chicago, IL

9:00 a.m. – 9:20 a.m.
  Evolving Therapeutic Approaches to 4 Challenging Cardiomyopathies:
  Myocarditis, Takotsubo, AL/TTR Amyloid and Non-Compaction LV
Matthew S. Maurer, MD, FACC
New York, NY

9:20 a.m. – 9:40 a.m.
  Assist Devices in Cardiac Decompensation – The 2 Challenges:
    1. LVAD Indications: Not to Early since Risks are High, but Not too Late,
    2. Assist Devices in the acute Decompensation – Impella vs ECMO
Sean P. Pinney, MD, FACC
Chicago, IL

9:40 a.m. – 10:10 a.m.
  Panel Discussion
Panelists: Drs. Bax, Maurer, McKenna, Pinney and Yancy

10:10 a.m. – 10:35 a.m.
  Break

Session VI: Rhythm Disorders, Contemporary and Future Topics of Focus
Chair: Vivek Y. Reddy, MD

10:35 a.m. – 11:00 a.m.
  Atrial Fibrillation 2020 – 14 Clinical Challenges
  Quality of Life & Preventing Stroke
Valentin Fuster, MD, PhD, MACC
New York, NY

11:00 a.m. – 11:25 a.m.
  Atrial Fibrillation - Catheter Ablation
Vivek Y. Reddy, MD
New York, NY

11:25 a.m. – 11:45 a.m.
  Atrial Fibrillation - Left Atrial Appendage Closure
  Who?, When?, How?, Results?
Jens Erik Nielsen-Kudsk, MD
Aarhus, Denmark

11:45 a.m. – 12:10 p.m.
  Ventricular Tachycardia - Catheter Ablation
  Who?, When?, How?, Results?
Karl-Heinz Kuck, MD
Hamburg, Germany
12:10 p.m. – 12:35 p.m.
Device Therapeutic Approaches CRTs Strict Indications, Subcutaneous ICDs, Leadless Pacemakers Follow-up Observations

Christophe Leclercq, MD
Rennes, France

12:35 p.m. – 1:00 p.m.
Panel Discussion
Panelists: Drs. Fuster, Kuck, Leclercq, Nielsen-Kudsk and Reddy

1:00 p.m. – 2:00 p.m.
Lunch Break

---

Valvular Heart Disease and Aorta — Challenges in 2020
Session VII: Management of Aortic Valve Disease and Aorta
Chair: Rick A. Nishimura, MD, MACC

2:00 p.m. – 2:30 p.m.
Aortic Valvular Stenosis: 3 Diagnostic and Management Challenges
- Congenital vs Senile,
- Asymptomatic vs Symptomatic,
- Low Flow/Low Gradient: CM 2ary to AS vs Dilated vs Restrictive

Presentation: (15 minutes)
Robert O. Bonow, MD, MACC
Chicago, IL

Critical Commentary: (15 minutes)
Drs. David H. Adams, Patrick T. O’Gara, Josep Rodes-Cabau and Samin K. Sharma

2:30 p.m. – 3:00 p.m.
Aortic Regurgitation: 3 Diagnostic and Management Challenges
- Associated or not Dilatation of the Aorta
- Asymptomatic vs Symptomatic
- EF Low/Intermediate vs Normal

Presentation: (15 minutes)
Rick A. Nishimura, MD, MACC
Rochester, MN

Critical Commentary: (15 minutes)
Drs. Ismail El-Hamamsy, David H. Adams, Robert O. Bonow, Patrick T. O’Gara, Josep Rodes-Cabau and Samin K. Sharma

3:00 p.m. – 3:30 p.m.
The Dilated Thoracic & Abdominal Aorta and Complicating Dissection
Evolving Understanding of the Basic Biology & Management

Presentation: (15 minutes)
Valentin Fuster, MD, PhD, MACC
New York, NY

Critical Commentary: (15 minutes)
Ismail El-Hamamsy, MD, PhD,
New York, NY

3:30 p.m. – 3:50 p.m.
Break

Session VIII: Management of Mitral Regurgitation, Tricuspid Regurgitation and Hypertrophic Cardiomyopathy
Chair: David H. Adams, MD, FACC

3:50 p.m. – 4:20 p.m.
Mitral Regurgitation: 3 Diagnostic and Management Challenges
- Primary vs Secondary
- Asymptomatic vs Symptomatic
- EF Low/Intermediate vs Normal
Presentation: (15 minutes)
Patrick T. O’Gara, MD, MACC
Boston, MA

Critical Commentary: (15 minutes)
Drs. Robert O. Bonow, Rick A. Nishimura, Josep Rodes-Cabau & Samin K. Sharma

4:20 p.m. – 4:50 p.m.
Tricuspid Regurgitation: 3 Diagnostic and Management Challenges
- Primary vs Secondary to Pulmonary Hypertension
- Residual from Previous Left Sided Valvular Surgery or not
- Symptomatic with RVEF Low/Intermediate vs Normal
Presentation: (15 minutes)
Josep Rodes-Cabau, MD
Quebec, QB, Canada

Critical Commentary: (15 minutes)
Drs. Robert O. Bonow, Rick A. Nishimura, Patrick T. O’Gara and Samin K. Sharma

4:50 p.m. – 5:20 p.m.
Hypertrophic Cardiomyopathy – 5 Challenging Questions
- Genetics/Acquired, Myectomy Types, CD, Apical/Aneurysm
Presentation: (15 minutes)
Rick A. Nishimura, MD, MACC
Rochester, MN

Critical Commentary: (15 minutes)
Drs. Robert O. Bonow, Patrick T. O’Gara, Josep Rodes-Cabau, and Samin K. Sharma

5:20 p.m.
Adjourn